NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] Attending PAGE, WCOP or ACOP? take advantage of this special rate for Advanced Phoenix NLME courses

From: Simon Davis <>
Date: Wed, 4 May 2016 17:33:44 +0000

We are running our always popular advanced NLME course at a special rate of=
 $1000 for a 2 day session before these three conferences; enter Discount c=
ode: "WCOP2016" for any of the 3 courses below.
PAGE - 6-7 June 2016
WCOP - 19-20 August 2016
ACOP - 27-29 October 2016

Course name: "(CL-301) Advanced Pharmacometrics PK/PD Modeling Course using=
 Phoenix NLME"

  Best regards, Simon.

Get tips and discuss Phoenix with other users;

Topics covered include

-Covariate Analysis
- Random effect parameters
-Between Subject variability
-Between occasion variability

Phoenix modelling language (PML)
- Language through built in and graphical
- Language through "edit as textual "mode only
- Dobefore, doafter, while, double
- Sequence statement
- while(1), while(condition)
- if statement
- Simulate statement
- Random number generators

How does the program thinks
Program stopping, when, why and implications
Maximum a posteriori / Posthoc estimates
Population Simulation
Clinical trial designs
Special simulation and fitting tools available in pml
Simulate: unif(), norm()
Fitting: lpois,lnegbin

Literature based modeling and Simulation exercises
Lelanidomide Population PK
  -Normal likelihood
 - Use of "edit as textual" based on built in and graphical template
 -Pk responses

Population PKPD modeling of eltrombopag in subjects with advanced solid tum=
ors with chemotherapy induced thrombocytopenia
 - Normal likelihood
 - Transit compartments
 -PK/PD responses

Population PK/PD of homocysteine in the presence of Methotrexate
- PK/PD/covariate analysis

Population pharmacokinetics and exposure toxicity analysis of Vatalanib in =
 patients with myelodysplastic syndromes
- Standard Population PK analysis
- Volume Kinetics for Infusion Fluids

Target- mediated pharmacokinetic/pharmacodynamic model based meta-analysis =
and dosing regimen optimization of a long-acting release formulation of exe=
natide in patients with type 2 diabetes mellitus
 -Edit as textual
Senior Scientific Consultant
Pharsight- A CertaraT Company

Work Mobile     : +44 7500 190 212 >> note the new numb=
Facsimile       : +1 801 991 7145
Personal Mobile : +44 7980 832 666
Phoenix 6.4 and Validation Suite available
Sign up for the Certara blog at
___________________________________ (some upcoming course in EU below, s=
ee website for US, India etc.)
Intermediate PKPD with Phoenix (Tue-Fri) 16-19 May, Copenhagen, Denmar=
Advanced Phoenix NLME (Mon-Tue before PAGE) 6-7 June, Lisbon, Portugal
Intro to Phoenix WinNonlin, 21-23 Sep 2016, Copenhagen, Denmark
Intermediate PKPD with Phoenix (Tue-Fri) 18-21 Oct, London, UK
Intro to Phoenix NLME (Tue-Wed)  15-16 Nov, Barcelona, Spain
Intro to Phoenix WinNonlin, 5-7 Dec 2016, Frankfurt, Germany
Intro to Phoenix IVIVC, 7-8 Dec 2016, Frankfurt, Germany NOTICE: Th=
e information contained in this electronic mail message is intended only fo=
r the personal and confidential use of the designated recipient(s) nam=
ed above. This message may be an attorney-client communication, may be prot=
ected by the work product doctrine, and may be subject to a protective=
 order. As such, this message is privileged and confidential. If the r=
eader of this message is not the intended recipient or an agent responsible=
 for delivering it to the intended recipient, you are hereby notified =
that you have received this message in error and that any review, diss=
emination, distribution, or copying of this message is strictly prohibited.=
 If you have received this communication in error, please notify us im=
mediately by telephone and e-mail and destroy any and all copies of this =

 copies). Thank you. buSp9xeMeKEbrUze

Received on Wed May 04 2016 - 13:33:44 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: Once subscribed, you may contribute to the discussion by emailing: